Bionorica has sold C³ to Canopy Growth
Bionorica has sold its cannabis business, C³ (Cannabinoid Compound Company), to Canopy Growth Corporation, a world-leading diversified cannabis and hemp company based in Smiths Falls, Canada. The selling price amounts to Euro 225.9 million. The strategic goal is to quickly and consistently develop and expand the international markets to meet the needs of a steadily growing number of patients. Bionorica will support Canopy Growth in this regard in future. Both parties see great opportunities in the further clinical research of the cannabis plant and its constituents. To this end, Bionorica SE and Canopy Growth have agreed to collaborate in long-term research.
The product portfolio comprises API & compounding kits for Dronabinol (THC), Cannabidiol (CBD) as well as other cannabinoid synthesis products for mainly pharmaceutical or analytical applications. Key therapeutic areas are pain and palliative treatment, oncology and neurology addressing a broad spectrum of chronic and severe illnesses.
C³ was founded in 2014 by Bionorica SE, one of the world’s leading producers of herbal medicines, as a holding company for the companies Bionorica ethics and THC Pharm. Both Bionorica ethics and THC Pharm have for almost two decades been researching and developing the key therapeutic ingredients of the cannabis flower: tetrahydrocannabinol and cannabidiol. Under the umbrella of C³, research, production and marketing have been pooled and optimized.
Canopy Growth Corporation is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and softgel capsule forms. Canopy Growth offers medically approved vaporizers through the Company’s subsidiary, Storz & Bickel GmbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents.
Lincoln International acted as the exclusive financial advisor to the seller, managing a competitive M&A process with strong interest from various parties.
Meet our Senior Team
Building long-term relationships is key for me personally – I want to be the advisor of trust for my clients.
Dr. Michael Drill
Managing Director | CEO Germany | Chairman of the Management BoardFrankfurt
View More Transactions
Lincoln International advised toob in raising £300m of capital to support its network expansion
Lincoln International advised Colmec Group, a Scandinavian distribution platform for truck tire lifecycle management, on its sale to Norvestor
Lincoln International advised Ambienta and other shareholders on the sale of Next Imaging to Azimut Libera Impresa
Lincoln International advised Private shareholders on the sale of ISM Heinrich Krämer to Protective Industrial Products, a portfolio company of Odyssey Investment Partners
Lincoln International advised Deutsche Invest Capital Partners on the sale of Loibl Förderanlagen to Martin Group
Lincoln International advised ECA International in its investment from Pelican Capital
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.